INTRODUCTION
Gene transfer of OCT3/4, SOX2, KLF4, and c-Myc to somatic cells generates human induced pluripotent stem cells (iPSCs) [1] [2] [3] although c-MYC is not required for iPSC generation [4] . Human iPSCs are indistinguishable from human embryonic stem cells (ESCs) in terms of their longterm self-renewal ability and their in vivo pluripotency [3, 5] . The starting cells for iPSC generation should be appropriately chosen to generate normal or aberrant iPSC lines for the purpose of regenerative medicine or cancer research/therapy. Human iPSC lines for regenerative medicine would be ideally generated from normal neonatal tissues [3] that are typically free of postnatal aberrant mutations and epigenetic changes. Human iPSCs (or iPSC-like cells) have also been generated from cancer cell lines [6, 7] , the somatic cells from familial cancer patients [8, 9] , and pancreatic ductal adenocarcinomas [10] . For cancer research/therapy, it is of great interest to generate iPSCs from heterogeneous cancer tissues. In our recent study [11] , human iPSC lines were clonally generated from a heterogeneous mixture of primary cells derived from gastric tissues or colon cancer tissues and were subjected to microarray gene expression analysis. The resultant iPSC lines expressed all ESC-enriched genes including POU5F1, SOX2 and NANOG that are essential for self-renewal ability and pluripotency [5, 12] at a level equivalent to those of the typical human iPSC line (201B7) [1] . Genome-wide gene expression patterns were used to categorize the reference iPSC line 201B7 and the iPSC lines derived from distinct cancer tissues into three different groups. The gene expression profiles of these iPSC lines demonstrated differences derived from their distinct starting tissues and similarity and heterogeneity derived from their common starting heterogeneous tissues. More recently, it was reported that reference component analysis (RCA), an algorithm that substantially improves clustering accuracy, was developed to robustly cluster single-cell transcriptomes [13] . The RCA of single-cell transcriptomes elucidated cellular heterogeneity in human colorectal cancer [13] . In this study, iPSC technology and next-generation sequencing were used to resolve genotype variation among single cells within a heterogeneous cancer tissue. The genomic DNA of ten iPSC lines that were clonally generated from human colon cancer tissue was analyzed and compared with the genomic DNA from their cancer tissue of origin and matched adjacent non-cancerous tissue.
MATERIALS AND METHODS

Tissues derived from a single colon cancer patient
This study was conducted with the approval of the Institutional Review Boards of the National Cancer Center of Japan and the Japanese Collection of Research Bioresources (JCRB), National Institutes of Biomedical Innovation, Health and Nutrition. Written informed consent from a single donor was obtained for the use of the tissues for research. The anonymous remnant noncancerous and cancerous tissues were provided by the JCRB Tissue Bank. The tissues were derived from the surgical waste material from an operation performed on a 55-year-old Japanese male S-shaped colon cancer patient.
Primary cell culture from cancer tissues
Heterogeneous primary cell culture from the colon cancer tissues was prepared as previously described [11] . Briefly, the tissues were washed with Hank's balanced salt solution (HBSS) and minced into pieces with scissors. The pieces were further washed with HBSS. DMEM with collagenase was added to the tissue precipitates and mixed at 37 ℃ for 1 h on a shaker. After washing with DMEM, cells were seeded on collagen-coated dishes and cultured in DMEM supplemented with 10% FBS.
Generation of human iPSC lines
The study was approved by the Institutional Recombinant DNA Advisory Committee. Heterogeneous primary cells from the cancer tissue were cultured for 24 h at approximately 5%-10% confluency and then incubated with a pantropic retrovirus vector solution (OCT3/4, KLF4, and SOX2) at 37 ℃ for an additional 24 h. The vector solution was prepared as previously described [14] . Mitomycin C-treated mouse embryonic fibroblasts (MEFs, ReproCell) were seeded and co-cultured with the primary cells following the retroviral infection. The culture medium was replaced with MEF-conditioned ESC medium every 3 d until the cell layer was fully confluent and then further refreshed with mTeSR1 medium (STEMCELL Technologies) every day. Each independent colony was isolated from the culture using forceps under a microscope. The independent iPSC lines were sub-cultured with MEF in gelatincoated 24-well plates.
Expansion and passage culture of human iPSC lines
Human iPSC lines were cultured with the MEFs in primate ESC, ReproStem (ReproCell) or mTeSR1 medium in gelatincoated dishes [11] . The expanded iPSC lines were treated with a dissociation solution (ReproCell) or 0.25% trypsin-EDTA (Gibco) and passaged in media supplemented with 10-20 μmol/L Y-27632 to avoid cell death [3] . Independent iPSC lines were passaged from the 24-well plates into 6-well plates, further expanded into 100-mm dishes, and minimally passaged in 100-mm dishes under similar culture conditions. Each genomic DNA sample was prepared from independent iPSC lines.
Real-time RT-PCR analysis
Total RNA was prepared using the miRNeasy Mini Kit (Qiagen). Reverse transcription of the RNA was carried out using an iScript™ Advanced cDNA Synthesis Kit for RT-qPCR (Bio-Rad). Quantitative PCR was carried out with an SsoAdvanced Universal SYBR ® Green Supermix using the CFX96 Real-Time PCR Detection System (BioRad). PCR primer sets for OCT3/4, SOX2, NANOG, ZFP42, and GAPDH are listed in Supplemental Table 1 . PCR data were analyzed using CFX Manager Software (Bio-Rad). PCR data from the iPSC 201B7 [1] RNA were used as a positive control, and PCR data from cancer tissue-derived iPSC lines are presented as quantification cycle (Cq) values.
Target selection and sequencing
Target sequencing was conducted for twelve DNA samples from the cancer tissues, the non-cancerous tissues, and the ten iPSC lines. Genomic DNA was extracted from each of twelve samples using the DNeasy Blood AND Tissue Kit (Qiagen), sheared into approximately 150-bp fragments, and used to make a library for multiplexed paired-end sequencing with the SureSelect XT Reagent Kit (Agilent Technologies). The constructed library was hybridized to biotinylated cRNA oligonucleotide baits from the SureSelect XT Human Kinome Kit (Agilent Technologies)
for target enrichment. Targeted sequences were purified by magnetic beads, amplified, and sequenced on an Illumina HiSeq2000 platform in a paired-end 101 bp configuration.
Mapping and single-nucleotide variant calling
Adapter sequences were removed by cutadapt (v1.2.1). After quality control, reads were mapped to the human reference genome hg19 using BWA (ver.0.6.2). Mapping results were corrected using Picard (ver. 
RESULTS
Human iPSC lines derived from colon cancer tissues
The human iPSC lines CC1-1, CC1-2, CC1-7, CC1-8, CC1-9, CC1-11, CC1-12, CC1-17, CC1-18, and CC1-25
were clonally generated from heterogeneous primary cells cultured from colon cancer tissue. The iPSC lines were expanded serially with MEFs in gelatin-coated dishes. The cancer tissue-derived iPSCs were indistinguishable in morphology from typical (fibroblast-derived) human iPSCs under conventional culture with MEFs (upper panels in Figure 1 and Supplemental Figure 1 ). The human iPSCs formed colonies consisting of very small cells and were efficiently passaged at a high recovery ratio with the addition of 10-20 μmol/L Y-27632 to the cell culture medium. Human iPSCs were also cultured with feederfree mTeSR1 medium in BD Matrigel TM -coated 100-mm dishes and showed a high nucleus-to-cytoplasm ratio (lower panels in Figure 1 and Supplemental Figure 1 ).
Expression of human ESC-essential genes
ESC-essential gene expression of the cancer tissuederived iPSC lines was quantitatively analyzed by realtime RT-PCR. All ten iPSC lines expressed POU5F1, SOX2, and NANOG, which are essential for self-renewal and pluripotency, at a level equivalent to those of the reference iPSC line (Supplemental Table 2 ). The study results support previously published microarray data showing that cancer tissue-derived iPSCs equally express ESC-enriched genes [11] .
Next-generation sequencing
The target region (SureSelect Human Kinome) in genomic DNA samples from the ten iPSC lines, their starting cancer tissues, and the matched adjacent noncancerous tissues was analyzed using next-generation sequencing. The target region of approximately 3.2 Mb covers the genome of the coding region of all known protein kinase genes and selected oncogenes and tumor suppressor genes, for a total of 612 genes (Supplemental Table 3 ). The original reads (2.6-4.0 Gb of sequence) were obtained from each genomic DNA sample by sequencing ( Table 1 ). The modified reads were generated from the original reads ( Table 2 ). The results of the mapped reads, the sequencing depth, and target capture are summarized in Tables 3-5 . The average depth on the target region ranged from 317 to 496. More than 99.76% of the target region was covered with at least 8 × depth for high-quality genotype calls (variant call quality score ≥ 30).
Non-synonymous SNVs compared with hg19
After sequencing, the reads underwent bioinformatics analysis ( Figure 2 ). Through comparison with the human reference genome hg19, the non-synonymous SNVs (missense, nonsense or read-through) were called on the target region (on and near DNA target enrichment baits) of twelve samples (the ten iPSC lines, their starting cancer tissues, and the matched adjacent non-cancerous tissues). Of the resulting 378 non-synonymous SNVs (Supplemental Table 4 ), 50 were novel SNVs (not reported in dbSNP135 or 1000 Genomes, Supplemental Table 5 ).
Confirmed genotypes of the twelve samples
Of the 378 non-synonymous SNVs from the twelve samples, 40 were distinct heteroallelic genotypes and included known SNVs in the 612 sequenced gene target region. Supplemental Table 6 lists the forty SNVs that were distinct among the human iPSC lines, their starting cancer tissue, and the matched adjacent non-cancerous tissues. The allelic depth and genotype quality of thirteen of the forty SNVs were validated and manually curated using the Integrative Genomics Viewer ( Figure 2 ).
Mutated genotypes of cancer tissue-derived iPSC lines
The chromosome number, genome position, novelty, gene symbol, and mutation type of the thirteen confirmed SNVs are shown in Table 6 ; the allelic depth is shown in Table 7 ; and the genotype is shown in (Table 6) , of the iPSC lines were different from that of the non-cancerous tissue sample (Table 8) . Nevertheless, the genotypes of the iPSC samples were also different from that of the starting cancer tissue sample. The heteroallelic read sequences of ULK4, TRRAP, and WNK1 of the starting cancer tissue sample consisted of 247|2 of A|C, 240|1 of G|C, and 246|2 of C|T, respectively (Table 7) . Although the major read sequences indicated the genotypes of the non-cancerous tissues, the minor reads indicated missense mutations. The potential heteroallelic genotypes were identical to the mutated genotypes of the CC1-25, CC1-12, and CC1-8 iPSC lines. Meanwhile, the genotypes of all ten of the iPSC lines were different from the mutated genotypes in ERBB2 and MKNK2 of the cancer tissues and were identical to those of the non-cancerous tissues and human reference genome hg19 (Table 8) . Thus, all analyzed iPSC lines were preferentially generated from starting cells without mutations in ERBB2 and MKNK2, except for those generated from mature cancer cells. Furthermore, the iPSC lines CC1-7 and CC1-17 did not have any confirmed mutated genotypes despite originating from the cancer tissue.
DISCUSSION
The ten iPSC lines were clonally generated from a heterogeneous mixture of primary cells derived from the colon cancer tissue of a single patient. The genomes of the ten iPSC lines were analyzed using next-generation sequencing. The genomes of the starting cancer tissue and matched adjacent non-cancerous tissue from the same donor were also analyzed. The target region for analysis was the human kinome and cancer-related genes that are typically mutated in human tumors. A total of 378 non-synonymous SNVs identified from samples of the ten iPSC lines and the cancerous and non-cancerous tissues were identified by comparing the sequence reads to the human reference genome hg19. Most of the nonsynonymous SNVs showed the genotype of the noncancerous tissue, suggesting their germline origin. The SNVs of the ten iPSC lines were compared with those of the cancerous and non-cancerous tissues. Forty of the SNVs were distinct genotypes among all twelve samples. Thirteen of the forty SNVs were confirmed using allelic depth, genotype quality, and the Integrative Genomics Viewer.
In eight of the ten iPSC lines, one or two novel, nonsynonymous SNVs (heteroallelic missense or nonsense mutation) in EIF2AK2, TTN, ULK4, TSSK1B, FLT4, STK19 , STK31, TRRAP, WNK1, PLK1 or PIK3R5 were identified as genotypes different from those of the non-cancerous tissue. Unexpectedly, all the SNVs were not identical to the genotypes found in the cancer tissues. Because of minor read sequences, the potential genotype of ULK4, TRRAP or WNK1 in the cancer tissues was implied. The sequences indicated a missense mutation in ULK4, TRRAP or WNK1 identical to that found in the iPSC lines CC1-25, CC1-12, and CC1-8. Accordingly, there is a possibility that each iPSC line was generated from a starting cell from a minor cell population with a mutation in ULK4, TRRAP, or WNK1 that was present within the cancer tissue. The minor read sequences could be confirmed by ultra-deep sequencing to support the potential heteroallelic genotypes. Interestingly, two iPSC lines CC1-7 and CC1-17 did not have any confirmed mutated genotypes despite originating from the cancer tissues. Therefore, the two iPSC lines might be generated from non-cancerous cells such as pre-cancer (stem) cells and cancer-associated fibroblasts [15, 16] . Table 5 Target capture
The target region, as covered by the SureSelect Human Kinome Kit, was approx. of genetic mutations and epigenetic aberration [17] . It is likely that the genotypes of pre-metastatic cancer cells in multiple clonal evolutions would be different from those of non-metastatic cancer cells. Meanwhile, genotypes of major mature cancer cells would be identical to those of cancer tissues; therefore, it was expected that genotypes of cancer tissue-derived iPSC lines would be identical to those of their starting cancer tissues. It was reported that ERBB2 mutations were persistent in 3.6% of patients with colorectal cancer [18] . Indeed, a mutated genotype in ERBB2 of the colon cancer tissues was also identified in this study.
Nevertheless, the genotypes of the ten iPSC lines were different from the mutated ERBB2 and MKNK2 genotypes in the cancer tissues and were identical to those of the non-cancerous tissues and the human reference genome hg19. This result suggests that the starting cells for the iPSC lines did not carry the mutations in ERBB2 and MKNK2 present in the cancer tissues. It is conceivable that the non-mutated genotypes of each iPSC line were identical to those of non-cancerous cells such as pre-cancer (stem) cells, stroma cells and immune cells that existed within the tissue. Each iPSC line was clonally established by selecting an independent single colony expanded from a putative single starting cell originating from heterogeneous cancer tissue. The genome sequence of each iPSC line was derived from its starting single cell. As a result, each iPSC line conserved the non-mutated ERBB2 and MKNK2 genotypes that originated from their respective starting single cells. Interestingly, all ten iPSC lines were not generated from cell populations containing either a mutated ERBB2 and/or a mutated MKNK2. Thus, the genotypes of each iPSC line provide information on the genomic origin of the starting single cell derived from the heterogeneous cancer tissue.
Although the cause of the preference for the genomic origin of their starting cells was not clarified in this study, it seems that chemicals [19] , gene sets [1, 4] , gene transfer [20, 21] , or inventive pre-culture [22, 23] , in which the starting cells might be preferentially specified, can affect iPSC generation. Accordingly, materials and methods can be optimized to generate normal or aberrant iPSC lines for the purposes of regenerative medicine or cancer research/therapy. Cancer tissues comprise (pre-) cancer (stem) cells, pre-metastatic cancer cells, stromal cells (such as mesenchymal stem cells, cancer-associated fibroblasts [15, 16, 24] and tumor endothelial cells) and immune cells (such as tumor-associated macrophages [25] , dendritic cells [26] and tumor-infiltrating T cells [23] ). Therefore, such a cell-derived iPSC line might be useful for immune-cell therapy [27] with cellular vaccines [28] , dendritic cells [29] [30] [31] [32] or tumor antigen-specific cytotoxic T cells [23] , in addition to the development of models of carcinogenesis [33] [34] [35] and drug discovery tools [36, 37] . For the purposes of regenerative medicine, human iPSCs are ideally generated from normal neonatal tissues [3, [38] [39] [40] that are typically inexperienced of postnatal aberrant mutations or epigenetic changes. By contrast, aging and sun-exposed skin carries thousands of evolving clonal cells carrying cancer-causing mutations [41, 42] . Indeed, genetic mutations accumulate gradually over a lifetime, even in human somatic stem cells [43] . For this reason, cell sources for iPSC generation should be selected based on the given field of research. Furthermore, iPSC lines with few or no mutations need to be established by the modification of existing methodology [39, 44, 45] , as cell lines with de novo mutations not originating from the starting cells are not desired [46] [47] [48] [49] [50] . Nevertheless, cancer tissue-derived iPSCs might give rise to such de novo mutations, as their starting cells might have already suffered from an aberration (epigenetics or gene expression) associated with de novo mutations or cancer. Indeed, colon cancer tissuederived iPSC lines exhibited unique gene expression profiles, with particular upregulation of FAM19A5 and SLC39A7 [11] , in comparison with those of the typical iPSC line 201B7 [1] . FAM19A5 and SLC39A7 were found to be expressed at lower levels in many human iPSC and ESC lines based on a free online expression atlas (Amazonia!, http://amazonia.transcriptome.eu/search.php) [51] .
FAM19A5 was reported as a novel cholangiocarcinoma biomarker [52] , while SLC39A7 is an intracellular zinc transporter and a hub for tyrosine kinase activation related to diseases such as cancer [53] . The analysis of iPSC genomes might expose rare single cells, such as an authentic cancer stem cells present within cancer tissues. Thus, next-generation sequencing of heterogeneous cancer tissue-derived iPSC lines might reveal potential aberrations or changes originating from the cancer tissue.
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Background
Starting cells for induced pluripotent stem cell (iPSC) generation should be appropriately adopted to generate normal or aberrant iPSC lines for use in regenerative medicine or cancer research/therapy. Human iPSC lines for regenerative medicine would be ideally generated from normal neonatal tissues, as they are typically free of postnatal aberrant mutations and epigenetic changes. For cancer research/therapy, it is of great interest to generate iPSCs that originate from heterogeneous cancer tissues.
Research frontiers
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similarity and heterogeneity derived from their common starting heterogeneous tissue.
Innovations and breakthroughs
This is the first study to analyze human iPSC lines clonally generated from a heterogeneous mixture of primary cells derived from cancer tissues using nextgeneration sequencing. Eight of the ten iPSC lines had single-nucleotide variants with de novo or pre-existing mutations originating from a minor population within the cancer tissues. Meanwhile, all other genotypes of the iPSC lines were not mutated as in the original cancer tissues. Two of the ten iPSC lines did not possess any confirmed mutated genotypes despite having been derived from cancer tissue. These results suggest that the majority of iPSC lines originated from starting cells other than major cancer cells. Thus, the genotypes of iPSC lines can be used to trace the genotypes of the starting single cells.
Applications
It is conceivable that cancer tissues are made up of not only pre-cancer (stem) cells and pre-metastatic cancer cells but also stroma cells (such as mesenchymal stem cells, cancer-associated fibroblasts and tumor endothelial cells) and immune cells (such as tumor-associated macrophages, dendritic cells and tumor-infiltrating T cells). These other cell types might serve as targets for drug discovery and immune-cell therapy against cancer. Therefore, such a cell-derived iPSC line might be useful for immune-cell therapies such as cancer vaccines, dendritic cells and tumor antigen-specific cytotoxic T cells, in addition to the development of models of carcinogenesis and drug discovery tools.
Terminology
Most single-nucleotide variants are heteroallelic genotypes that are validated with allelic depth and genotype quality and manually curated using the Integrative Genomics Viewer. Deeper allelic depth of next-generation sequencing further resolves genotype variations among the starting single cells present within heterogeneous cancer tissues. In this way, the genotypes of the iPSC lines may be used to trace the genomic identity of their starting single cells derived from a heterogeneous cancer tissue.
